AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8631186 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper IUD with polypropylene tailstring
Number of subjects: 22
Study 8631186 — intervention group
Group type: COMPARATOR
Intervention: Copper IUD with polyethylene tailstring
Number of subjects: 22
Study 1658953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoxynol-9 (N-9), 150 mg, used cumulatively four times a day for 14 days
Number of subjects: 14
Study 6623339 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological examination
Number of subjects: 41
Study 6623339 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky functional rating
Number of subjects: 41
Study 6623339 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) brain scanning
Number of subjects: 41
Study 6623339 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 41
Study 6623339 — intervention group
Group type: COMPARATOR
Intervention: Karnofsky rating plus neurological examination
Number of subjects: 41
Study 6623339 — intervention group
Group type: COMPARATOR
Intervention: CT scan alone
Number of subjects: 41
Study 31600598 — intervention group
Group type: EXPERIMENTAL
Intervention: XF-73 0.5mg/g 2% gel
Number of subjects: 60
Study 31600598 — intervention group
Group type: EXPERIMENTAL
Intervention: XF-73 2.0mg/g 2% gel
Number of subjects: 60
Study 31600598 — intervention group
Group type: EXPERIMENTAL
Intervention: XF-73 0.5mg/g 4% gel
Number of subjects: 60
Study 31600598 — intervention group
Group type: COMPARATOR
Intervention: 4% viscosified placebo gel
Number of subjects: 60
Study 31226190 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant planning and freehand placement (control group, n = 26)
Number of subjects: 73
Study 31226190 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereolithographic guide (T1, n = 24)
Number of subjects: 73
Study 31226190 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐printed guide (T2, n = 23)
Number of subjects: 73
Study 31226190 — intervention group
Group type: COMPARATOR
Intervention: Conventional implant planning and freehand placement (control group)
Number of subjects: 73
Study 31226190 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereolithographic guide (T1)
Number of subjects: 73
Study 31226190 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐printed guide (T2)
Number of subjects: 73
Study 28365025 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed rest
Number of subjects: 0
Study 28365025 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 25032713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg loading dose, followed by 5 days of 80 mg)
Number of subjects: 218
Study 25032713 — intervention group
Group type: COMPARATOR
Intervention: Regular-dose atorvastatin (10 mg)
Number of subjects: 218
Study 25032713 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 218
Study 24858750 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg lycopene/day for 2 weeks with oral prophylaxis (full mouth scaling and root planing completed within 24 hours)
Number of subjects: 20
Study 24858750 — intervention group
Group type: COMPARATOR
Intervention: Oral prophylaxis only
Number of subjects: 20
Study 21996647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg oral fast-dissolving tablet)
Number of subjects: 0
Study 21996647 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib (40 mg intravenous infusion)
Number of subjects: 0
Study 21996647 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (6 mg subcutaneous injection)
Number of subjects: 0
Study 19243818 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-12 300 ng/kg subcutaneously twice weekly for 24 weeks
Number of subjects: 48
Study 19243818 — intervention group
Group type: COMPARATOR
Intervention: IL-12 250 ng/kg I.V. daily for 5 days every 3 weeks (initial treatment)
Number of subjects: 48
Study 16521225 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN with polaprezinc 300 mg (regimen A, n=41)
Number of subjects: 83
Study 16521225 — intervention group
Group type: COMPARATOR
Intervention: CIFN monotherapy (regimen B, n=42)
Number of subjects: 83
Study 14709761 — intervention group
Group type: EXPERIMENTAL
Intervention: Women whose partners participated in the interview
Number of subjects: 172
Study 14709761 — intervention group
Group type: EXPERIMENTAL
Intervention: Global severity index measuring total psychological distress
Number of subjects: 172
Study 11060183 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy without conscious sedation
Number of subjects: 451
Study 9103262 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilic dairy products bulgaricum and biostim (50 g daily for one month)
Number of subjects: 120
Study 9103262 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120
Study 1556540 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-held minirecord
Number of subjects: 0
Study 1556540 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no minirecord)
Number of subjects: 0
Study 6696322 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 20
Study 6696322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3295620 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly myelosuppressive maintenance chemotherapy after TAD9-induction and consolidation
Number of subjects: 81
Study 3295620 — intervention group
Group type: EXPERIMENTAL
Intervention: Double induction followed by consolidation and monthly maintenance
Number of subjects: 81
Study 3295620 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 81
Study 29273245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophins plus intrauterine insemination
Number of subjects: 666
Study 29273245 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonadotrophins plus intercourse
Number of subjects: 666
Study 29273245 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus intrauterine insemination
Number of subjects: 666
Study 29273245 — intervention group
Group type: COMPARATOR
Intervention: Clomifene citrate plus intercourse
Number of subjects: 666
Study 29273245 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine insemination
Number of subjects: 666
Study 27406394 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily) plus metformin [500 mg twice daily] (VLDM group)
Number of subjects: 3084
Study 27406394 — intervention group
Group type: COMPARATOR
Intervention: Metformin uptitration [1000 mg twice daily] (HDM group)
Number of subjects: 3084
Study 24680621 — intervention group
Group type: EXPERIMENTAL
Intervention: N. sativa oil (2.5ml, two times a day for 2 months)
Number of subjects: 34
Study 24680621 — intervention group
Group type: COMPARATOR
Intervention: Placebo (liquid paraffin, 2.5ml, two times a day for 2 months)
Number of subjects: 34
Study 23440923 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time alerts based on a predictive algorithm for clinical deterioration.
Number of subjects: 20031
Study 20414637 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg daily for 6 weeks)
Number of subjects: 16
Study 20414637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19099925 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/d)
Number of subjects: 30
Study 19099925 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17255643 — intervention group
Group type: EXPERIMENTAL
Intervention: NeReBot robotic training (about 4 h/week for 4 weeks)
Number of subjects: 20
Study 17255643 — intervention group
Group type: COMPARATOR
Intervention: Standard post-stroke multidisciplinary rehabilitation without robotic training
Number of subjects: 20
Study 12801148 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping skills training group
Number of subjects: 0
Study 12801148 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional discussion)
Number of subjects: 0
Study 10830451 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypo-osmolar ORS (224 mmol/L)
Number of subjects: 70
Study 10830451 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (311 mmol/L)
Number of subjects: 70
Study 8777679 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency oscillation
Number of subjects: 8
Study 8777679 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 8
Study 2057035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg daily)
Number of subjects: 804
Study 2057035 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (300 mg daily) plus Isosorbide Dinitrate (160 mg daily)
Number of subjects: 804
Study 2057035 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine-Isosorbide Dinitrate
Number of subjects: 804
Study 2057035 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and Hydralazine-Isosorbide Dinitrate
Number of subjects: 804
Study 6648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation challenge
Number of subjects: 10
Study 6648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge
Number of subjects: 10
Study 6648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise following hyperventilation
Number of subjects: 10
Study 6648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation following exercise
Number of subjects: 10
Study 6648867 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractoriness index (exercise first)
Number of subjects: 10
Study 31215874 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% ethylenediaminetetraacetic acid (EDTA) water solution
Number of subjects: 50
Study 31215874 — intervention group
Group type: EXPERIMENTAL
Intervention: 18% ethylenediaminetetraacetic acid (EDTA) gel
Number of subjects: 50
Study 31215874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 30019676 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 μg iodine/day from a multivitamin supplement for pregnant and lactating women
Number of subjects: 36
Study 27137626 — intervention group
Group type: EXPERIMENTAL
Intervention: DT+X (spinal cord detethering plus Xiao procedure)
Number of subjects: 20
Study 27137626 — intervention group
Group type: COMPARATOR
Intervention: DT (spinal cord detethering only)
Number of subjects: 20
Study 24317234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus 0.5% ropivacaine
Number of subjects: 62
Study 24317234 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine alone
Number of subjects: 62
Study 23047502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ferulate (SF) 150 mg three times daily for fourteen days
Number of subjects: 19
Study 19941078 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mometasone
Number of subjects: 217
Study 19941078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 18373403 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone genetic counseling (TGC)
Number of subjects: 0
Study 18373403 — intervention group
Group type: COMPARATOR
Intervention: Traditional face-to-face genetic counseling
Number of subjects: 0
Study 16145415 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaKinetic surgery
Number of subjects: 101
Study 16145415 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 101
Study 11687568 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix presentation of survey response options
Number of subjects: 1615
Study 11687568 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded presentation of survey response options
Number of subjects: 1615
Study 9344829 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human DNase (rhDNase)
Number of subjects: 0
Study 9344829 — intervention group
Group type: COMPARATOR
Intervention: Control (without rhDNase)
Number of subjects: 0
Study 8168887 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization in flexion cast
Number of subjects: 98
Study 8168887 — intervention group
Group type: COMPARATOR
Intervention: Immobilization in extension cast
Number of subjects: 98
Study 8168887 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization in a sling
Number of subjects: 98
Study 8168887 — intervention group
Group type: COMPARATOR
Intervention: Flexion cast
Number of subjects: 98
Study 2964995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ipratropium bromide and salbutamol therapy (combined)
Number of subjects: 46
Study 2964995 — intervention group
Group type: COMPARATOR
Intervention: Nebulized ipratropium bromide and salbutamol therapy (separately)
Number of subjects: 46
Study 2964995 — intervention group
Group type: COMPARATOR
Intervention: Swimming goggles
Number of subjects: 46
Study 2964995 — intervention group
Group type: COMPARATOR
Intervention: Continued antiglaucoma treatment
Number of subjects: 46
Study 31017585 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly serial self-measurements of waist and hip circumference combined with motivational text messages for 8 weeks
Number of subjects: 60
Study 31017585 — intervention group
Group type: COMPARATOR
Intervention: Control messages for 8 weeks
Number of subjects: 60
Study 26928205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tweet2Quit
Number of subjects: 160
Study 25842469 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosemary oil
Number of subjects: 100
Study 25842469 — intervention group
Group type: COMPARATOR
Intervention: Minoxidil 2%
Number of subjects: 100
Study 23642330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Anorexia Nervosa (CBT-AN)
Number of subjects: 63
Study 23642330 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 63
Study 21342066 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based screening with self-collected urine or vaginal specimens
Number of subjects: 0
Study 21342066 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based screening
Number of subjects: 0
Study 20073139 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve medication adherence
Number of subjects: 0
Study 17196664 — intervention group
Group type: COMPARATOR
Intervention: Right unilateral ECT (250% stimulus intensity of titrated threshold)
Number of subjects: 92
Study 17196664 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (150% of threshold)
Number of subjects: 92
Study 17196664 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (bifrontal and right unilateral ECT)
Number of subjects: 92
Study 15562054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine 0.1%
Number of subjects: 30
Study 15562054 — intervention group
Group type: COMPARATOR
Intervention: Epidural normal saline (Control)
Number of subjects: 30
Study 11903704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Education Programme for district nurses
Number of subjects: 104
Study 11903704 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 104
Study 9476461 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma IL-3 concentrations
Number of subjects: 23
Study 9476461 — intervention group
Group type: COMPARATOR
Intervention: Plasma IL-7 concentrations
Number of subjects: 23
Study 7944874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic Interview for Genetic Studies (DIGS)
Number of subjects: 0
Study 3061715 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution (dilute and hyperosmolar)
Number of subjects: 48
Study 3061715 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 48
Study 3061715 — intervention group
Group type: COMPARATOR
Intervention: Hyperosmolar saline solution
Number of subjects: 48
Study 3061715 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar amino acid solution
Number of subjects: 48
Study 31953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (VLC) diet (14%E carbohydrate, <50 g/d; 28%E protein; 58%E fat)
Number of subjects: 84
Study 31953540 — intervention group
Group type: COMPARATOR
Intervention: Higher Carbohydrate (HC) diet (53%E carbohydrate; 17%E protein; 30%E fat)
Number of subjects: 84
Study 31953540 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Carbohydrate (VLC) diet
Number of subjects: 84
Study 29142036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (5 or 10 mg twice daily) with concomitant glucocorticoids (GC)
Number of subjects: 3200
Study 29142036 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib (5 or 10 mg twice daily) without concomitant glucocorticoids (GC)
Number of subjects: 3200
Study 29142036 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus glucocorticoids (GC)
Number of subjects: 3200
Study 29142036 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone
Number of subjects: 3200
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 1.5 mg/kg
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 5 mg/kg
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 15 mg/kg
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 45 mg/kg
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 8,400 mg
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A 10,800 mg
Number of subjects: 35
Study 27381392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (trial 1)
Number of subjects: 35
Study 27381392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (trial 2)
Number of subjects: 35
Study 27381392 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAA4549A
Number of subjects: 35
Study 25925398 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral escalating immunotherapy (10 mg to 2 g with 2-week increments)
Number of subjects: 0
Study 25925398 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral escalating immunotherapy
Number of subjects: 0
Study 25925398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22913981 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 22
Study 22913981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21799027 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children aged 6-11 years
Number of subjects: 490
Study 21799027 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese adolescents aged 12-17 years
Number of subjects: 490
Study 21799027 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults (general population)
Number of subjects: 490
Study 21799027 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender among 12- to 17-year-olds and 18- to 44-year-olds
Number of subjects: 490
Study 20133267 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir monotherapy
Number of subjects: 60
Study 20133267 — intervention group
Group type: COMPARATOR
Intervention: HAART regimen (Control)
Number of subjects: 60
Study 16710356 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan plus cilnidipine
Number of subjects: 87
Study 16710356 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 87
Study 15464494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate (0.08 microg x kg(‐1) x min(‐1))
Number of subjects: 108
Study 11762557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ortho Evra contraceptive patch
Number of subjects: 30
Study 8669219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1200 mg) administered by infusion pump over 24 hrs
Number of subjects: 20
Study 8669219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (200 mg) administered by infusion pump over 24 hrs
Number of subjects: 20
Study 8669219 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study 2677055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flurbiprofen (100 mg/day) + toothbrushing (A)
Number of subjects: 25
Study 2677055 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + toothbrushing (B)
Number of subjects: 25
Study 2677055 — intervention group
Group type: COMPARATOR
Intervention: Oral flurbiprofen (100 mg/day) only (C)
Number of subjects: 25
Study 359250 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg diflunisal twice daily
Number of subjects: 37
Study 359250 — intervention group
Group type: COMPARATOR
Intervention: 400 mg ibuprofen 3-times daily
Number of subjects: 37
Study 31372680 — intervention group
Group type: EXPERIMENTAL
Intervention: Button fixation
Number of subjects: 30
Study 31372680 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 30
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbendazim resistance (CarR)
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethofencarb resistance (DieR)
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Iprodione resistance (IprR)
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Boscalid resistance (BosR)
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzimidazole-resistant isolates with E198V mutation
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual resistance to carbendazim and diethofencarb
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: BosR isolates with H272R mutation
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: IprR isolates
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple resistance phenotypes
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: CarR isolates with E198V/K mutations
Number of subjects: 257
Study 30964418 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of half maximal effective concentrations
Number of subjects: 257
Study 28360027 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin pump treatment
Number of subjects: 317